GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » Long-Term Capital Lease Obligation

Cidara Therapeutics (FRA:20D0) Long-Term Capital Lease Obligation : €1.14 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Long-Term Capital Lease Obligation?

Cidara Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €1.14 Mil.

Cidara Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 (€2.13 Mil) to Dec. 2024 (€1.85 Mil) and declined from Dec. 2024 (€1.85 Mil) to Mar. 2025 (€1.14 Mil).

Cidara Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€3.28 Mil) but then declined from Dec. 2023 (€3.28 Mil) to Dec. 2024 (€1.85 Mil).


Cidara Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Cidara Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Long-Term Capital Lease Obligation Chart

Cidara Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.17 - 3.28 1.85

Cidara Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.93 2.58 2.13 1.85 1.14

Cidara Therapeutics  (FRA:20D0) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Cidara Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines